NIH PAR · NHLBI · U24
PAR-27-013: Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic…
- NOFO number
- PAR-27-013
- Type
- PAR
- Activity code
- U24
- Primary institute
- NHLBI · National Heart, Lung, and Blood Institute
- Clinical trials
- Required
- Posted
- Mar 18, 2026
- Opens
- May 2, 2026
- Expires
- Nov 3, 2028
PAR-27-013 due dates
6 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| June 02, 2026 | July 02, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 02, 2026 | November 02, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 01, 2027 | March 01, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 02, 2027 | July 02, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 01, 2027 | November 01, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 01, 2028 | March 01, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 01, 2028 | June 30, 2028 | Not Applicable | November 2028 | January 2029 | April 2029 |
| October 02, 2028 | November 02, 2028 | Not Applicable | March 2029 | May 2029 | July 2029 |
What its predecessor PAR-22-193 funded
PAR-27-013 reissues PAR-22-193. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 23 projects and $39.2M in FY2022–FY2026.
Projects funded
23
Distinct projects, FY2022–FY2026
New awards
23
Type 1 (new project) award records
NIH funding
$39.2M
Award dollars under PAR-22-193, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 3 | 3 | $2.4M |
| FY2024 | 11 | 8 | $8.2M |
| FY2025 | 17 | 6 | $12.1M |
| FY2026 | 22 | 6 | $16.6M |
Institutions with the most funding
- Research Triangle Institute$7.9M · 2 projects
- Johns Hopkins University$5.8M · 3 projects
- Duke University$5.6M · 3 projects
- Beth Israel Deaconess Medical Center$3.2M · 1 project
- Icahn School of Medicine at Mount Sinai$2.8M · 2 projects
- Utah State Higher Education System--University of Utah$2.4M · 1 project
- Wake Forest University Health Sciences$1.9M · 1 project
- Oregon Health & Science University$1.6M · 1 project
Funding institutes
- NHLBI$39.2M · 53
Activity codes funded
- U2453 records
Most recent new awards
- 2/2 Precision Tapering of Biological Therapy in Asthma: Identifying Predictors of Optimized Dupilumab Dosing (opens NIH RePORTER)
Pennsylvania State Univ Hershey Med Ctr · 1U24HL188704-01 · NHLBI · Notice Sep 10, 2026
$581KU24
- 2/2 GLobal trial Of Bromocriptine for PeriPartum CardioMyopathy (GLOBal PPCM) (opens NIH RePORTER)
University of Alabama at Birmingham · 1U24HL177575-01A1 · NHLBI · Notice Sep 9, 2026
$434KU24
- 2/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy (opens NIH RePORTER)
New England Research Institutes, Inc. · 1U24HL185609-01 · NHLBI · Notice Sep 8, 2026
$806KU24
- 1/2- Antiplatelet Therapy in Spontaneous Coronary Artery Dissection (APT-SCAD) (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1U24HL181196-01A1 · NHLBI · Notice Sep 7, 2026
$1.3MU24
- 2/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease (opens NIH RePORTER)
Johns Hopkins University · 1U24HL183678-01A1 · NHLBI · Notice Sep 7, 2026
$1.4MU24
- 2/2 Catheter Ablation Versus Antiarrhythmic and Heart Failure Drug Therapy in Preserved Ejection Fraction Heart Failure (CABANA-HF) (opens NIH RePORTER)
Duke University · 1U24HL183692-01 · NHLBI · Notice Jul 9, 2026
$1.6MU24
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-27-013. Contact the program officer at the institute that fits your research before applying.
- NHLBI · National Heart, Lung, and Blood Institute
- none
Related notices
NIH lists no related notices for PAR-27-013 yet.
Award terms
- Application types allowed
- New Resubmission Revision The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the requested project award period. The period of award is expected to be 5 years. Up to 7 years may be requested if strongly justified. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-22-193.
- Companion NOFOs: PAR-27-012.
Other open NOFOs for U24
- RFA-CA-27-020Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)NCI · next due Oct 19, 2026
- RFA-CA-27-021Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)NCI · next due Oct 19, 2026
- RFA-AG-27-010Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)NIA · next due Nov 10, 2026
- RFA-HG-27-008IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)NHGRI · next due Dec 14, 2026
- PAR-28-057Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)NCI · next due Jan 25, 2027
- RFA-CA-28-004Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)NCI · next due Feb 11, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.